Javier Munoz, MD, MS, FACP: I have been given the opportunity to discuss the case of a 66-year-old woman with mantle cell lymphoma. She was treated in 2017. She was treated with R-CHOP [rituximab cyclophosphamide, hydroxydaunorubicin hydrochloride, vincristine, prednisone] and R-DHAP [rituximab, dexamethasone, cytarabine, cisplatin], followed by autologous stem cell rescue, and she achieved a partial remission. She was subsequently prescribed rituximab maintenance. In 2019 she experienced a clinical relapse and was started on acalabrutinib, achieving stable disease.
Currently, she complains of a 3-month history of fatigue, nausea, and dyspnea. Her medical history includes having diabetes, which is medically well controlled. On physical exam, she has lymphadenopathy. Indeed, a new lymph node biopsy showed cyclin D1 positivity and CD10 and CD20 positivity, and the FISH [fluorescence in situ hybridization] showed the translocation of chromosomes 11 and 14. The imaging, not surprisingly, confirmed the physical findings of lymphadenopathy, widespread adenopathy above and below the diaphragm. A bone marrow biopsy confirmed that the patient had mantle cell lymphoma as well.
Treatment was started with lymphodepleting chemotherapy—fludarabine and cyclophosphamide—followed by a single infusion of CAR [chimeric antigen receptor] T cells.
Transcript edited for clarity.
Case: A 66-Year-Old Woman With Mantle Cell Lymphoma
History
Currently
Liso-Cel Delivers Deep, Durable Responses in R/R MCL
January 11th 2024High complete response rates and low incidences of cytokine release syndrome and neurological events were observed when patients with relapsed or refractory mantle cell lymphoma were treated with lisocabtagene maraleucel.
Read More
ZUMA-18 Study Shows Brexu-cel's Therapeutic Potential in MCL
January 3rd 2024In an interview with Targeted Oncology, Andre Goy, MD, discussed the potential of brexucabtagene autoleucel for the treatment of patients with relapsed/refractory mantle cell lymphoma and how 2 studies provide support for use of the agent in this patient population.
Read More